PierianDx Introduces PDx Score to Quickly Prioritize Actionable Variants, While Expanding Industry-Leading Knowledgebase
by Josh Forsythe, on March 24, 2015
ST LOUIS, MO – PierianDx announced today that its genomic testing platform will soon produce a PDx Score giving clinicians prioritized, actionable and deeply informed data for a quicker diagnosis. PierianDx also announced the addition of clinical trials, FDA drug labels, and treatment guidelines from the National Comprehensive Cancer Network and the American Society of Clinical Oncology to its industry-leading knowledgebase.
To be launched in June, the PDx Score is produced through a highly complex algorithm that sorts through PierianDx’s completely integrated and comprehensive knowledgebase and associates the most relevant information with the patient’s clinical and genetic data.
The PDx Score is a proprietary feature of PierianDx’s Clinical Genomicist Workstation, a robust informatics software solution that completely and efficiently manages next-generation sequencing processes and shares comprehensive clinical insights for somatic cancer and constitutional assays.
Along with the introduction of the PDx Score, PierianDx is expanding its knowledgebase on which the analysis and scoring is based. Incorporated into the database are molecular matching to clinical trials, FDA drug labels, and treatment guidelines from NCCN and ASCO. These important content enhancements add to an already extensive database of up-to-the-moment curated publications, biological information, computational predictions, population frequency data, clinical research correlations, and disease variants reported in clinical databases.
“The new PDx Score meets a critical need in clinical NGS-based testing — providing an evidence-based system to evaluate potentially pathologic and other actionable variants,” said Dr. Jonathan Heusel, Chief Medical Officer of Genomics and Pathology Services at Washington University in St. Louis. “The most clinically relevant, or ‘actionable,’ variants are prioritized, facilitating a more efficient evaluation of variants and minimizing the chances of missing —or misclassifying—something. This feature will help us to enrich our reporting with the most relevant information for individual cases, improving the ability to guide decisions on the most effective treatments sooner.”
PierianDx enables clinical labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. In use since 2011, and constantly growing with new patient and clinical and research data, PierianDx’s proprietary Clinical Genomicist Workstation software, knowledgebases, IT backbone and workflow management tools provide clinical labs everything they need to manage their next-generation sequencing processes. For more information, please visit www.pieriandx.com or @PierianDx on Twitter.